Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 893 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis May 25, 2023 EMA Recommends Extension of Indications for Selpercatinib April 15, 2026 Programme Highlights of the ESMO Virtual Congress 2020 [ESMO Media Alert] August 28, 2020 Cancer Research UK spin-out gets US approval to trial unique T... June 18, 2021 Load more HOT NEWS Teacher Is Glad She Asked for More Testing After Mammogram Failed... Cowboys Fan Battling Metastatic Breast Cancer Gets Surprise From Team’s Quarterback Honeybee Venom May Be the Next Treatment for Aggressive Breast Cancer New Research in Treating Metastatic Breast Cancer, Preventing Breast Cancer, and...
